<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00682695</url>
  </required_header>
  <id_info>
    <org_study_id>NS36695</org_study_id>
    <secondary_id>2U01NS036695-15A1</secondary_id>
    <nct_id>NCT00682695</nct_id>
  </id_info>
  <brief_title>Genetic and Environmental Risk Factors for Hemorrhagic Stroke</brief_title>
  <acronym>GERFHS</acronym>
  <official_title>Genetic and Environmental Risk Factors for Hemorrhagic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Maryland, College Park</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke University, Durham, NC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Columbia University, New York, New York</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Illinois Chicago, Chicago, Illinois</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find risk factors for hemorrhagic stroke.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed research builds on the most robust, statistically significant and replicated
      association identified to determine the mechanism by which it may relate to intracerebral
      hemorrhage (ICH) risk. Given that ICH is an extreme phenotype on a spectrum of manifestations
      of cerebral small vessel disease, the findings that emerge from our proposed studies offer
      the promise of broad impact for research and treatment in a wide variety of cerebrovascular
      disorders.

      In the genetic epidemiology of hemorrhagic stroke, we propose to perform an in-depth
      fine-mapping of the entire 1q22 genomic region (~250kb) to investigate whether genetic
      variants influence gene expression that correlates with ICH status or changes in expression
      over time in ICH cases. As existing samples were not processed for gene expression analysis,
      we will recruit 500 non-lobar ICH cases (~150 black, ~350 white) and 1000 controls (300
      black, 700 white) to correlate sequence variation with gene expression levels in the same
      samples. Identified associations will be replicated in 6,000 cases of ICH and 9,361
      individuals in the CHARGE consortium with MRI white matter hyperintensity volume measurements
      and 5,000 controls. The current proposal takes the next logical step by pursuing the most
      promising findings of our GWAS to complete the following aims:

      Specific Aim #1: Perform deep DNA sequencing of Chr 1q22 among non-Hispanic white and black
      ICH cases and controls to identify all genomic variation within these regions and test the
      following:

      Hypothesis #1a: Variants strongly associated with ICH risk at 1q22 are either directly causal
      or in linkage disequilibrium to causal variants that influence ICH risk, and sequencing of
      these regions will reveal both common and rare variants that exert this causal influence.

      Hypothesis #1b: Variants strongly associated with ICH risk at 1q22 will be associated with
      risk of, or severity of, leukoaraiosis.

      Specific Aim #2: Prospectively collect DNA, RNA, and serum on ICH cases and geographic region
      site-specific controls both at the time of ICH and in the convalescent period. We will
      perform RNA expression profiling between cases and controls and over time in cases. We will
      compute expression quantitative trait locus (eQTL) analysis with SNPs arising from Aim 1. We
      will also determine whether alternatively spliced transcripts differ between cases and
      controls.

      Hypothesis #2a: Variation in gene expression or alternatively spliced transcripts affects
      risk of ICH.

      Hypothesis #2b: Variations identified by DNA sequencing will affect gene expression and/or
      alternatively spliced transcripts that affect risk of ICH.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 1997</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Perform deep DNA sequencing of Chr 1q22</measure>
    <time_frame>Ongoing to be completed at the end of June 2021</time_frame>
    <description>Perform deep DNA sequencing of Chr 1q22 among non-Hispanic white and black ICH cases and controls to identify all genomic variation within these regions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Collect and analyze DNA, RNA, and serum on ICH cases and matched control participants.</measure>
    <time_frame>Ongoing to be completed at the end of June 2021</time_frame>
    <description>Collect and analyze DNA, RNA, and serum on ICH cases and matched controls both at the time of ICH and in the convalescent period. We will perform RNA expression profiling between cases and controls and over time in cases.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Participants who have had a hemorrhagic stroke at University of Maryland, University of Cincinnati, Massachusetts General Hospital, Duke University, Columbia University and University of Chicago Illinois, age 18 years or greater. Ability of the patient or legal representative to provide informed consent. Racial/ethnic category meets one of the following: African American, Caucasian or Hispanic.
Healthy volunteers who are matched to the study cases with hemorrhagic stroke within +/- 5 years of age, same gender and same race.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood DNA, RNA and CBC
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This study will be limited to physician-reviewed cases of people who have had a hemorrhagic
        stroke.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 or older

          -  Resident (6 months or longer) within the recruitment center

          -  Fulfillment of the criteria for spontaneous ICH

          -  No evidence of trauma, brain tumor/metastases or infectious processes as a cause of
             the hemorrhage

          -  Ability of the patient or legal representative to provide consent for an interview,
             blood pressure determinations and DNA sampling

        Exclusion Criteria:

          -  N/A
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Woo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lee A Gilkerson, RN, BSN</last_name>
    <phone>513-558-6140</phone>
    <email>Lee.gilkerson@uc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Illinois Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maureen Hillman</last_name>
      <phone>312-355-3863</phone>
      <email>hillmann@uic.edu</email>
    </contact>
    <investigator>
      <last_name>Fernando Testai, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Watson</last_name>
      <phone>410-706-1902</phone>
      <email>tiwatson@som.umaryland.edu</email>
    </contact>
    <investigator>
      <last_name>Steven Kittner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Kourkoulis</last_name>
      <phone>617-726-5358</phone>
      <email>CKOURKOULIS@PARTNERS.ORG</email>
    </contact>
    <investigator>
      <last_name>Jonathan R, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Angela Velazquez</last_name>
      <phone>212-305-6071</phone>
      <email>aqv2113@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>David Roh, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreea Podgoreanu</last_name>
      <phone>919-681-4054</phone>
      <email>andrea.podgoreanu@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Michael L James, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee A Gilkerson, RN, BSN</last_name>
      <phone>513-558-6140</phone>
      <email>Lee.gilkerson@uc.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel Woo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Woo D, Sauerbeck LR, Kissela BM, Khoury JC, Szaflarski JP, Gebel J, Shukla R, Pancioli AM, Jauch EC, Menon AG, Deka R, Carrozzella JA, Moomaw CJ, Fontaine RN, Broderick JP. Genetic and environmental risk factors for intracerebral hemorrhage: preliminary results of a population-based study. Stroke. 2002 May;33(5):1190-5.</citation>
    <PMID>11988589</PMID>
  </reference>
  <reference>
    <citation>Kissela BM, Sauerbeck L, Woo D, Khoury J, Carrozzella J, Pancioli A, Jauch E, Moomaw CJ, Shukla R, Gebel J, Fontaine R, Broderick J. Subarachnoid hemorrhage: a preventable disease with a heritable component. Stroke. 2002 May;33(5):1321-6.</citation>
    <PMID>11988610</PMID>
  </reference>
  <reference>
    <citation>Woo D, Kissela BM, Khoury JC, Sauerbeck LR, Haverbusch MA, Szaflarski JP, Gebel JM, Pancioli AM, Jauch EC, Schneider A, Kleindorfer D, Broderick JP. Hypercholesterolemia, HMG-CoA reductase inhibitors, and risk of intracerebral hemorrhage: a case-control study. Stroke. 2004 Jun;35(6):1360-4. Epub 2004 Apr 15.</citation>
    <PMID>15087556</PMID>
  </reference>
  <reference>
    <citation>Woo D, Haverbusch M, Sekar P, Kissela B, Khoury J, Schneider A, Kleindorfer D, Szaflarski J, Pancioli A, Jauch E, Moomaw C, Sauerbeck L, Gebel J, Broderick J. Effect of untreated hypertension on hemorrhagic stroke. Stroke. 2004 Jul;35(7):1703-8. Epub 2004 May 20.</citation>
    <PMID>15155969</PMID>
  </reference>
  <reference>
    <citation>Flaherty ML, Woo D, Haverbusch M, Sekar P, Khoury J, Sauerbeck L, Moomaw CJ, Schneider A, Kissela B, Kleindorfer D, Broderick JP. Racial variations in location and risk of intracerebral hemorrhage. Stroke. 2005 May;36(5):934-7. Epub 2005 Mar 24.</citation>
    <PMID>15790947</PMID>
  </reference>
  <reference>
    <citation>Sauerbeck LR, Khoury JC, Woo D, Kissela BM, Moomaw CJ, Broderick JP. Smoking cessation after stroke: education and its effect on behavior. J Neurosci Nurs. 2005 Dec;37(6):316-9, 325.</citation>
    <PMID>16396084</PMID>
  </reference>
  <reference>
    <citation>Woo D, Kaushal R, Chakraborty R, Woo J, Haverbusch M, Sekar P, Kissela B, Pancioli A, Jauch E, Kleindorfer D, Flaherty M, Schneider A, Khatri P, Sauerbeck L, Khoury J, Deka R, Broderick J. Association of apolipoprotein E4 and haplotypes of the apolipoprotein E gene with lobar intracerebral hemorrhage. Stroke. 2005 Sep;36(9):1874-9. Epub 2005 Aug 11.</citation>
    <PMID>16100021</PMID>
  </reference>
  <reference>
    <citation>Woo D, Sekar P, Chakraborty R, Haverbusch MA, Flaherty ML, Kissela BM, Kleindorfer D, Schneider A, Khoury J, Sauerbeck LR, Deka R, Broderick JP. Genetic epidemiology of intracerebral hemorrhage. J Stroke Cerebrovasc Dis. 2005 Nov-Dec;14(6):239-43.</citation>
    <PMID>16557295</PMID>
  </reference>
  <reference>
    <citation>Flaherty ML, Haverbusch M, Kissela B, Kleindorfer D, Schneider A, Sekar P, Moomaw CJ, Sauerbeck L, Broderick JP, Woo D. Perimesencephalic subarachnoid hemorrhage: incidence, risk factors, and outcome. J Stroke Cerebrovasc Dis. 2005 Nov-Dec;14(6):267-71.</citation>
    <PMID>16518463</PMID>
  </reference>
  <reference>
    <citation>Flaherty ML, Woo D, Haverbusch M, Moomaw CJ, Sekar P, Sauerbeck L, Kissela B, Kleindorfer D, Broderick JP. Potential applicability of recombinant factor VIIa for intracerebral hemorrhage. Stroke. 2005 Dec;36(12):2660-4. Epub 2005 Nov 3.</citation>
    <PMID>16269646</PMID>
  </reference>
  <reference>
    <citation>Woo D, Kaushal R, Kissela B, Sekar P, Wolujewicz M, Pal P, Alwell K, Haverbusch M, Ewing I, Miller R, Kleindorfer D, Flaherty M, Chakraborty R, Deka R, Broderick J. Association of Phosphodiesterase 4D with ischemic stroke: a population-based case-control study. Stroke. 2006 Feb;37(2):371-6. Epub 2005 Dec 22.</citation>
    <PMID>16373644</PMID>
  </reference>
  <reference>
    <citation>Flaherty ML, Haverbusch M, Sekar P, Kissela B, Kleindorfer D, Moomaw CJ, Sauerbeck L, Schneider A, Broderick JP, Woo D. Long-term mortality after intracerebral hemorrhage. Neurology. 2006 Apr 25;66(8):1182-6.</citation>
    <PMID>16636234</PMID>
  </reference>
  <reference>
    <citation>Flaherty ML, Haverbusch M, Sekar P, Kissela BM, Kleindorfer D, Moomaw CJ, Broderick JP, Woo D. Location and outcome of anticoagulant-associated intracerebral hemorrhage. Neurocrit Care. 2006;5(3):197-201.</citation>
    <PMID>17290088</PMID>
  </reference>
  <reference>
    <citation>Kaushal R, Pal P, Alwell K, Haverbusch M, Flaherty M, Moomaw C, Sekar P, Kissela B, Kleindorfer D, Chakraborty R, Broderick J, Deka R, Woo D. Association of ALOX5AP with ischemic stroke: a population-based case-control study. Hum Genet. 2007 Jun;121(5):601-7. Epub 2007 Mar 27.</citation>
    <PMID>17387518</PMID>
  </reference>
  <reference>
    <citation>Eden SV, Morgenstern LB, Sekar P, Moomaw CJ, Haverbusch M, Flaherty ML, Broderick JP, Woo D. The role of race in time to treatment after subarachnoid hemorrhage. Neurosurgery. 2007 May;60(5):837-43; discussion 837-43.</citation>
    <PMID>17460518</PMID>
  </reference>
  <reference>
    <citation>Kaushal R, Woo D, Pal P, Haverbusch M, Xi H, Moomaw C, Sekar P, Kissela B, Kleindorfer D, Flaherty M, Sauerbeck L, Chakraborty R, Broderick J, Deka R. Subarachnoid hemorrhage: tests of association with apolipoprotein E and elastin genes. BMC Med Genet. 2007 Jul 31;8:49.</citation>
    <PMID>17672902</PMID>
  </reference>
  <reference>
    <citation>Flaherty ML, Kissela B, Woo D, Kleindorfer D, Alwell K, Sekar P, Moomaw CJ, Haverbusch M, Broderick JP. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology. 2007 Jan 9;68(2):116-21.</citation>
    <PMID>17210891</PMID>
  </reference>
  <reference>
    <citation>Kharofa J, Sekar P, Haverbusch M, Moomaw C, Flaherty M, Kissela B, Broderick J, Woo D. Selective serotonin reuptake inhibitors and risk of hemorrhagic stroke. Stroke. 2007 Nov;38(11):3049-51. Epub 2007 Sep 27.</citation>
    <PMID>17901378</PMID>
  </reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 20, 2008</study_first_submitted>
  <study_first_submitted_qc>May 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2008</study_first_posted>
  <last_update_submitted>June 10, 2019</last_update_submitted>
  <last_update_submitted_qc>June 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cincinnati</investigator_affiliation>
    <investigator_full_name>Daniel Woo</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>stroke</keyword>
  <keyword>brain attack</keyword>
  <keyword>hemorrhagic stroke</keyword>
  <keyword>risk factors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

